The FDA Adverse Event Reporting System (FAERS) was used to evaluate the associations between oral anticoagulants (OACs) and acute kidney injury (AKI). Disproportionality analysis were applied to data
Adverse drug events classified as “causal” or “contributory” to hospitalization, “possibly” or “definitely avoidable” and attributed to STOPP-listed PIMs.
